Losartan Potassium Tablet, Film Coated
Product Images NDC 72789-179

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72789-179). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 01)

Chemical structure diagram of Losartan Potassium, showing its molecular configuration including rings, bonds, and functional groups with potassium ion (K+) present.*

FDA Label Image

Image002 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 02)

A line graph comparing the percentage of patients with a primary endpoint over 66 study months between two drugs: Atenolol (dotted line) and Losartan potassium (solid line). The graph shows adjusted risk reduction of 13% with a p-value of 0.021, indicating statistical significance in the difference between the two treatments.*

FDA Label Image

Image003 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 03)

A line chart comparing the percentage of patients with fatal and non-fatal stroke over study months up to 66 months, for Atenolol (dotted line) and Losartan potassium (solid line). The graph shows lower stroke rates over time for Losartan potassium, indicating a 25% adjusted risk reduction (p=0.001) compared to Atenolol.*

FDA Label Image

Image004 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 04)

A forest plot comparing event rates and hazard ratios of Losartan Potassium vs. Atenolol for Primary Composite and Stroke (Fatal/Non-fatal) outcomes across various patient subgroups including age, gender, race, ISH status, diabetes, and history of cardiovascular disease (CVD). The plot shows the number of patients, event rates, and the hazard ratio with confidence intervals, indicating whether the data favors Losartan Potassium or Atenolol.*

FDA Label Image

Image005 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 05)

A line graph comparing the percentage of patients with an event over time in months between Losartan potassium and placebo groups. The y-axis shows percentage of patients with events from 0 to 60%, and the x-axis shows time in months up to 48. The graph indicates a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

72789179 Label (72789179)

Packaging label for LOSARTAN POTASSIUM USP 50 MG film-coated tablets, containing 90 tablets per bottle. The label shows product name, strength, quantity, and identification details including NDC 72789-179-90. It is labeled by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. The label includes lot number C21E11 and expiration date 09/2022. Dosage instructions blanks are present, with bilingual text in English and Spanish.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.